PB1934 QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE AFTER STOPPING TREATMENT BY TYROSINE KINASE INHIBITORS AT LONG‐TERM FOLLOW‐UP

• Published in: HemaSphere 2019-06, Vol.3 (S1), p.879-880
• Main Authors: Nikitina, T., Ionova, T., Petrova, A., Chelysheva, E., Shukhov, O., Nemchenko, I., Porfir’eva, N., Bykova, A., Tsyba, N., Turkina, A.
• Format: Article
• Language: English
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/01.HS9.0000566232.65976.68

Background: It is reasonable to incorporate the quality of life (QoL) assessment into the comprehensive evaluation of treatment outcomes in chronic phase chronic myeloid leukemia (CML CP) patients (pts) with deep molecular response (DMR) who enter the treatment‐free remission (TFR) phase and stop therapy by tyrosine kinase inhibitors (TKIs). Aims: We aimed to study QoL in CML CP pts who had stable DMR at long‐term follow‐up. Methods: The CML CP pts who had received therapy by any TKI ≥ 3 years (yrs) and had maintained DMR (MR4 or deeper with BCR‐ABL ≤0.01% IS) were enrolled into the prospective multicenter study RU‐SKI which has been conducted within the clinical approbation supported by Ministry of Health of RF. TKI were resumed in a case of major molecular response (MMR, BCR‐ABL>0.1% IS) loss. The QoL questionnaires RAND SF‐36 and EORTC QLQ C30 were filled out by the pts before stopping TKI treatment (base‐line) and at different time points after TKI treatment discontinuation. QoL analysis was performed in patients who were in TFR lasting >12 months. The paired Wilcoxon test was used for the statistical analysis. Results: In total, 98 CML CP pts with DMR were enrolled in the trial. Mean age was 46 yrs; 48% were males; 13% had high Sokal risk score; 80.6% pts were with comorbidity. The TKIs before treatment cessation were the following: imatinib in 67 (78%) pts, second‐generation (2G) TKIs were used as 1st line and as 2nd line in 11 (11.2%) and in 20 (20,4%) pts respectively. Toxicity to TKI was revealed in 62/98 pts (63.2%). During TFR phase TKI withdrawal syndrome was observed in 41/98 pts (41.8%). Me TFR duration was 24 mos (range 14–42). MMR loss and TKI resuming was in 46 (47%) pts. In QoL analysis at long term follow‐up 51/98 pts were included. In the vast majority of pts (46/51) during TFR phase QoL scores improved (11.8%) or were stable (78.4%) as compared with base‐line. Physical functioning (80.7 vs 87.2) and general health (63.3 vs 69.7) significantly improved (p≤0.01); Integral QoL Index (IQoLI) increased from 0.575 to 0.633 (p